Shedding Light on a Novel PI3K Inhibitor: Enabling Isoform-Specific Inhibition to Establish Clinical Success
Time: 3:40 pm
day: Conference Day One
Details:
- Examining the mode of action of a novel, non-ATP competitive PI3Kd inhibitor and its pharmacological activity
- Dissecting isoform-dependent toxicity profiles for an improved assessment of therapeutic index
- Highlighting the importance of a selectivity-matched PK profile to optimize the therapeutic potential for clinical development
